Tag

Precision Medicine

All articles tagged with #precision medicine

public-health9 days ago•12 min saved

Birth-genome screening could reshape early childhood care

Global genomic newborn-screening studies (eg, GUARDIAN, BabyScreen+, BabyDetect) are testing broad sequencing on dried-blood spots to flag treatable conditions not covered by traditional panels. Early results suggest confirmable findings in about 1–3% of infants, with some cases prompting life-saving interventions like bone-marrow transplants and earlier seizure treatment. While promising, researchers and ethicists debate cost, scalability, which genes/conditions to include, how to report results, and the potential for privacy or discrimination, as families’ experiences with counseling and communication vary.

via nature.com|

#genetic-disorders #genomics #newborn-screening

health16 days ago•6 min saved

DNA clues could forecast blood cancer progression years before diagnosis

A small study of 30 patients with myeloproliferative neoplasms found that new DNA changes in blood cells often appeared years before routine tests showed progression, with stable disease showing little genetic change and cases advancing toward myeloid leukemia. Some participants developed AML, while others remained stable; patterns were also linked to common treatments (hydroxyurea and azacitidine) but did not prove causation. The findings are associative and limited by size, yet suggest that serial DNA monitoring could enable earlier, more personalized monitoring and potentially guide future targeted interventions.

via Fox News|

#blood-cancer #dna-changes #early-detection

health25 days ago•6 min saved

Early screening and genomic profiling reshape lung cancer care

Lung cancer is the leading cause of cancer deaths, with NSCLC making up 80–85% of cases. Annual low-dose CT screening is recommended for adults 50–80 with a 20-pack-year history to detect cancer early. Comprehensive genomic profiling (biomarker testing) identifies actionable targets in many NSCLC cases, guiding personalized treatment and helping choose the best options—often after CGP results are available. Patients and families should advocate for CGP and awareness of screening, as early detection and precision medicine drive better outcomes.

via theSkimm|

#biomarker-testing #comprehensive-genomic-profiling #health

science1 month ago•7 min saved

KRAS Vaccine Shows Promise in Intercepting Pancreatic Cancer

Phase I trial of the KRAS-targeting vaccine mKRAS-VAX in 20 high‑risk individuals with pancreatic abnormalities showed 90% developed a robust immune response against six KRAS mutations, with memory cells detectable up to two years; no pancreatic cancer or high‑risk lesions developed during a median follow‑up of 16.5 months, and some precursor cysts regressed, supporting larger trials to test cancer interception.

via Inside Precision Medicine|

#cancer-vaccine #immunotherapy #kras

science2 months ago•8 min saved

Two Brain Signatures Divide Autism Into Distinct Subtypes

A large international study analyzed brain connectivity in about 940 autistic individuals and over 1,000 neurotypical controls, plus mouse models, and found two reproducible autism subtypes: a hyperconnectivity subtype with stronger inter-regional brain communication linked to immune-related pathways, and a hypoconnectivity subtype with reduced communication linked to synaptic pathways. Together these subtypes account for roughly 25% of autism cases and provide a biology-based framework for precision, personalized approaches to care.

via SciTechDaily|

#autism #brain-connectivity #fmri

health2 months ago•8 min saved

Smart drugs and precision medicine reshape cancer care at ASCO 2026

At ASCO 2026, researchers showcased ‘smart’ drugs that lift cancer cells’ invisibility cloaks to boost immunotherapy, with GRWD5769 plus cemiplimab shrinking tumors across several cancer types; other agents like ivonescimab and ozekibart show promise. A daily pill, daraxonrasib, doubled survival in metastatic pancreatic cancer, and mezigdomide added to therapy extended progression-free survival in multiple myeloma. A genomic test could allow many breast cancer patients to skip chemotherapy, while durvalumab added to chemoradiation may spare bladder-sparing surgery. Yet the Galleri multi-cancer test failed to reduce late-stage diagnoses, and rising incidence plus a looming cancer-care workforce gap stress health systems. Lifestyle changes such as better sleep and yoga may also improve outcomes for patients and survivors.

via The Guardian|

#asco #cancer #health

health2 months ago•39 min saved

Precision drugs extend cancer survival, turning it into a chronic condition

Advances in targeted therapies and precision medicine are enabling more people to live with cancer longer, shifting the disease from an imminent death sentence to a chronic condition for many patients. While survival improves across cancers, the era of targeted drugs also highlights ongoing challenges around access, affordability, and managing long-term treatment effects.

via Yahoo|

#cancer #health #healthcare-access

science3 months ago•5 min saved

Living Location Alters Aging Pace, Global Study Finds

A world-spanning study profiled 322 people from Europe, East Asia, and South Asia, analyzing DNA, proteins, fats, gut bacteria, immune markers, and metabolites. It found that ancestry provides a baseline for immunity, metabolism, and the microbiome, but where people live also reshapes aging trajectories—different populations show distinct aging patterns when relocated. East Asians outside their region aged biologically faster; Europeans aged more in Europe; gut microbes linked to sphingolipids were tied to telomere maintenance. The work underscores that precision medicine must account for both genetics and environment, and is published in Cell (2026).

via ScienceAlert|

#aging #environment #genetics

health4 months ago•7 min saved

Low-Dose Aspirin May Lower Colorectal Cancer Recurrence in Genetically Defined Patients

In the ALASCCA randomized trial across 33 hospitals, daily 160 mg aspirin after colorectal cancer surgery reduced recurrence by about half for patients with PI3K pathway mutations or related alterations (7.7% vs 14.1% and 7.7% vs 16.8%), with improved 3-year disease-free survival (~89% vs 79–81%), but higher severe side effects (16.8% vs 11.6%), suggesting a low-cost, genetics-driven post-surgical option pending guidelines.

via SciTechDaily|

#aspirin #clinical-trial #colorectal-cancer

health4 months ago•2 min saved

AI maps bowel cancer genetics to predict bevacizumab response

Researchers from the Institute of Cancer Research and RCSI used PhenMap, an AI tool, to analyze tumour genetics in 117 European advanced bowel cancer patients treated with bevacizumab, identifying patterns that predict non-response and potentially sparing thousands from ineffective treatment and side effects; the team plans to broaden testing and validate the approach for broader clinical use.

via The Guardian|

#ai #bevacizumab #bowel-cancer

health4 months ago•4 min saved

Genes influence GLP-1 weight-loss drug responses and side effects

Genetic differences, including a GLP1R variant and a GIPR variant, modestly affect how much weight people lose and their risk of nausea on GLP-1 obesity drugs; the weight-loss difference is small—about 1.7 lb more at eight months for one copy and ~3.3 lb for two copies. A GIPR variant was linked to higher nausea with tirzepatide. Separately, higher GLP-1 doses may confer cardiovascular benefits that seem independent of weight loss, suggesting dosing could optimize heart outcomes; tissue data indicate potential direct cardiac effects, warranting further study.

via Reuters|

#genetics #glp-1 #health

health4 months ago•6 min saved

DNA Clues Shed Light on Why GLP-1 Weight-Loss Varies

A large 23andMe GWAS of 27,885 GLP-1 med users links variants in GLP1R and GIPR to both weight-loss efficacy and nausea risk. A GLP1R missense variant (rs10305420) is associated with about 0.76 kg more weight loss per allele, while GIPR variants predict nausea specifically for tirzepatide (Zepbound/Mounjaro) but not semaglutide. 23andMe’s Total Health service now offers an interactive tool to estimate individual weight loss (roughly 6–20% of starting weight) and side-effect risk, moving toward precision obesity care where genetics is one piece of the puzzle though not the sole determinant.

via Neuroscience News|

#genetics #glp-1 #health

science4 months ago•8 min saved

Zebrafish Drug Screen Targets Autism Genes, Spotlighting Levocarnitine

Yale researchers used larval zebrafish to map how 774 FDA-approved drugs affect behaviors tied to autism-risk genes, building an open database of 520 compounds and identifying levocarnitine as a top rescuer for SCN2A and DYRK1A mutations; they validated the effect in human stem-cell–derived neurons, laying groundwork for precision, gene-targeted drug discovery in autism.

via Neuroscience News|

#autism #drug-repurposing #levocarnitine

health4 months ago•4 min saved

Two Gene Variants Linked to Different Weight-Loss Responses on Obesity Drugs

A Nature study of about 15,000 people using obesity drugs (Wegovy and Mounjaro) finds that certain genetic variants influence weight loss. One variant, especially in two copies, is associated with more weight loss; another variant may raise the risk of nausea. On average, participants lost 11.7% of body weight over eight months, with some achieving as much as 30%. Differences by sex, age, and ancestry, plus drug type, dose, duration and lifestyle, also shape outcomes. While promising for tailoring treatment, these findings are early and not yet practice-changing; further trials are needed to guide precision medicine in obesity care.

via BBC|

#genetics #health #obesity

neuroscience5 months ago•26 min saved

Two Brain Subtypes in ADHD Hint at Personalized Treatments

A study using structural MRI and machine learning identifies two distinct physical subtypes of ADHD. Subtype 1 shows increased gray matter in the frontal regions and cerebellum, linked to severe inattention; Subtype 2 shows widespread gray matter reductions in the cerebellum, frontal regions, and hippocampus, tied to higher overall severity and hyperactive/impulsive symptoms. Through a pseudo-time-series analysis and causal-network mapping, researchers reveal subtype-specific brain–behavior progression patterns, suggesting potential for personalized diagnosis and treatment, though longitudinal studies are needed to confirm progression and acknowledge cross-sectional design limitations.

via PsyPost|

#adhd #brain-subtypes #gray-matter